Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986490 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A | EXPERIMENTAL | - |
| Part 2A - Colorectal Cancer (CRC) | EXPERIMENTAL | - |
| Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC) | EXPERIMENTAL | - |
| Part 1B | EXPERIMENTAL | - |
| Part 2B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986490 | DRUG | Specified dose on specified days. |
| Bevacizumab | DRUG | Specified dose on specified days. |
Inclusion Criteria: * Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1. * CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B: i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986490 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-986490 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
BMS-986490 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied in patients with advanced solid tumors.
BMS-986490 is being studied in a Phase 1 clinical trial with the identifier NCT06730750. This trial evaluates BMS-986490 with or without bevacizumab in patients with advanced solid tumors and is enrolling approximately 360 participants in the United States, Australia, and Canada.
Yes, the Phase 1 clinical trial of BMS-986490 (NCT06730750) is randomized and controlled. The trial is not double-blinded, and it is currently active but not recruiting participants.